SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Davis JC, van der Heijde D, Dougados M, Woolley JM. Reduction in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494501.
  • 2
    Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995; 38: 499505.
  • 3
    Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumor necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 2006; 65: 71320.
  • 4
    Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 222433.
  • 5
    Davis JC, van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis from 96 weeks. Ann Rheum Dis 2005; 64: 155762.
  • 6
    Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al, for the ATLAS Study Group. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 213646.
  • 7
    Baraliakos X, Davis J, Tsuji W, Braun J. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005; 52: 121623.
  • 8
    Braun J, Landewe R, Hermann KG, Han J, Yan S, Williamson P, et al, for the ASSERT Study Group. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006; 54: 164652.
  • 9
    Haibel H, Rudwaleit M, Brandt HC, Grozdanovic Z, Listing J, Kupper H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two–week open-label trial. Arthritis Rheum 2006; 54: 67881.
  • 10
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 140011.
  • 11
    Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 226472.
  • 12
    Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65: 103843.
  • 13
    Van der Heijde D, Klareskog L, Rodriguez-Valverde V, Condreanu C, Bolosiu H, Melo-Gomes J, et al, for the TEMPO Study Investigators. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006; 54: 106374.
  • 14
    Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in spondyloarthropathy. J Rheumatol 2002; 29: 15835.
  • 15
    Bardos T, Szabo Z, Czipri M, Vermes C, Tunyogi-Csapo M, Urban RM, et al. A longitudinal study on an autoimmune murine model of ankylosing spondylitis. Ann Rheum Dis 2005; 64: 9817.
  • 16
    Lories RJ, Daans M, Derese I, Matthys P, Kasran A, Tylzanowski P, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006; 54: 173646.
  • 17
    Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115: 15719.
  • 18
    Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 15663.
  • 19
    Dijkmans BA, Wanders A, van der Heijde D, Fatenejad S. Radiographic results from a long-term multicenter trial of etanercept (Enbrel®) in patients with ankylosing spondylitis [abstract]. Arthritis Rheum 2005: 52 Suppl 9: S634.
  • 20
    Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab. Ann Rheum Dis 2005; 64: 14626.
  • 21
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, der Vlam K, Mielants H, et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26: 9615.
  • 22
    Creemers MC, Franssen MJ, van 't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005; 64: 1279.
  • 23
    Van der Heijde D, Landewe R, the ASAS Working Group. Selection of a method for scoring radiographs for ankylosing spondylitis clinical trials, by the Assessment in Ankylosing Spondylitis Working Group and OMERACT. J Rheumatol 2005; 32: 20489.
  • 24
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 25
    Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 228691.
  • 26
    Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short-term improvement after anti-TNFα therapy in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 143844.
  • 27
    Wanders A, Landewe R, Spoorenberg A, de Vlam K, Mielants H, Dougados M, et al. Scoring of radiographic progression in randomized clinical trials in ankylosing spondylitis: a preference for paired reading order. Ann Rheum Dis 2004; 63: 16014.
  • 28
    Van der Heijde D, Landewe R, van der Linden S. How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheum 2005; 52: 197985.
  • 29
    Maksymowych WP, Landewe R, Conner-Spady B, Dougados M, Mielants H, van der Tempel H, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007; 56: 184653.
  • 30
    Landewe R, Wanders AJ, Mielants H, Dougados M, van der Heijde D. Function in patients with ankylosing spondylitis is the resultant of patient reported disease activity and radiographic damage of the spine [abstract]. Ann Rheum Dis 2004; 63 Suppl 1: 889.
  • 31
    Wanders A, Landewe R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005; 64: 98894.
  • 32
    Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005; 52: 175665.
  • 33
    Schett G. Landewe R, van der Heijde D. Tumor necrosis factor blockers and structural remodeling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007; 66: 70911.
  • 34
    Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66: 9105.
  • 35
    Boers M, Kostense PJ, Verhoeven AC, van der Linden S, for the COBRA Trial Group. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001; 44: 22426.
  • 36
    Welsing PM, Landewe RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004; 50: 208293.
  • 37
    Van der Heijde D, Landewe R, Deodar A, Baker D, Han J, Xu W, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab [abstract]. Ann Rheum Dis 2007; 66 Suppl II: 856.